Comparative Pharmacology
Head-to-head clinical analysis: KAFOCIN versus TAZIDIME.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KAFOCIN versus TAZIDIME.
KAFOCIN vs TAZIDIME
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KAFOCIN (cefepime/enmetazobactam) is a combination of a fourth-generation cephalosporin (cefepime) and a β-lactamase inhibitor (enmetazobactam). Enmetazobactam inhibits extended-spectrum β-lactamases (ESBLs) and other class A β-lactamases, restoring cefepime's activity against β-lactamase-producing bacteria. Cefepime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell death.
Ceftazidime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and disrupting peptidoglycan cross-linking.
1 g IV every 8 hours.
1 to 2 g IV/IM every 8 hours; maximum 6 g/day.
None Documented
None Documented
Clinical Note
moderateCeftazidime + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Ceftazidime."
Clinical Note
moderateCeftazidime + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Ceftazidime."
Clinical Note
moderateWarfarin + Ceftazidime
"Warfarin may increase the anticoagulant activities of Ceftazidime."
Clinical Note
moderatePhenprocoumon + Ceftazidime
Terminal elimination half-life: 4.5-6.5 hours (increased to 12-18 hours in severe renal impairment; CrCl <30 mL/min).
1.9 hours (range 1.5-2.8 hours); prolonged in renal impairment (up to 20 hours in ESRD).
Renal: 60-80% unchanged; biliary/fecal: 15-30% as metabolites; total clearance ~120 mL/min.
Primarily renal (80-90% unchanged via glomerular filtration), biliary/fecal <5%.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic
"Phenprocoumon may increase the anticoagulant activities of Ceftazidime."